--- title: "Weekly Recap | INNOVENT BIO +7.39%, closing in on record highs" type: "News" locale: "en" url: "https://longbridge.com/en/news/296674142.md" description: "INNOVENT BIO rallied 7.39% this week to close at HK$102.4, outpacing the Hang Seng Index by roughly 5.2 percentage points. The four-day trading week opened with a dip to a low of HK$93.2 on Monday before recovering to HK$96.65. Tuesday saw a sharp pickup in volume, with the stock briefly touching HK$102.3 intraday and settling at HK$98.25. Wednesday brought heavy two-way action: the stock surged to an all-time high of HK$105.1 before pulling back to close at HK$101.2." datetime: "2026-08-22T06:51:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296674142.md) - [en](https://longbridge.com/en/news/296674142.md) - [zh-HK](https://longbridge.com/zh-HK/news/296674142.md) generator: "portal-rs" --- # Weekly Recap | INNOVENT BIO +7.39%, closing in on record highs ## The Week INNOVENT BIO rallied 7.39% this week to close at HK$102.4, outpacing the Hang Seng Index by roughly 5.2 percentage points. The four-day trading week opened with a dip to a low of HK$93.2 on Monday before recovering to HK$96.65. Tuesday saw a sharp pickup in volume, with the stock briefly touching HK$102.3 intraday and settling at HK$98.25. Wednesday brought heavy two-way action: the stock surged to an all-time high of HK$105.1 before pulling back to close at HK$101.2. Thursday was a quieter session, ending at HK$102.4. Weekly amplitude hit 12.53%, and average daily volume ran about 22% above the 60-day median, signalling elevated market engagement. ## Key Events The week’s narrative centred on two catalysts. After Tuesday’s close, attention turned to Innovent’s US$10.5 billion licensing deal with Pfizer, a move seen as a material step in the company’s global strategy. On Wednesday, Morgan Stanley lifted its target price on the stock to HK$138.5, citing robust first-half product revenue. Thursday morning, the company reported positive results from its mRNA cancer vaccine trial, driving a 3% intraday pop and lifting the broader Hong Kong vaccine sector. ## Analyst Ratings Coverage remains overwhelmingly constructive: 21 analysts rate the stock a buy, 7 rate it overweight, and 1 has a hold, with no sell or underweight calls among the 29 brokers tracked. The consensus rating is strong buy, and the consensus target price of HK$119.51 implies about 16.7% upside from the latest close. Individual targets range from HK$94.25 to HK$144.01, a wide spread that reflects differing views on the pace of value realisation. Innovent ranks first among 51 peers in the biotech sector. ## The Week Ahead Innovent reports its fiscal first-half 2026 results on Tuesday, 25 August. The market is looking for earnings per share of HK$0.5458 and revenue of roughly HK$11.4 billion. The print will be the next real test of whether the strong product-revenue growth that underpinned this week’s analyst upgrade can hold, and it will provide a valuation anchor for the recent Pfizer deal and mRNA pipeline. ## In Short Innovent charged towards record highs this week on a major licensing deal and pipeline progress, with broker ratings uniformly positive and the stock leading its sector. The current valuation — roughly 198 times earnings and 8.3 times book — prices in high expectations for the innovative-drug pipeline. The latest session’s fund-flow data paint a split picture: large-lot money was a net seller while medium and small lots were net buyers. The half-year report next week is the key catalyst: it will show whether the product-revenue momentum can justify the current premium. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [01801.HK](https://longbridge.com/en/quote/01801.HK.md) ## Related News & Research - [Spero Q2 FY26 net loss widens to $9.6 million; revenue posts no revenue](https://longbridge.com/en/news/295702309.md) - [Innovent Biologics signs exclusive deal with Daiichi Sankyo to commercialize Vanflyta in China](https://longbridge.com/en/news/295337735.md) - [REG - UIL Limited UIL Finance Ltd - Purchase of 2026 ZDP Shares](https://longbridge.com/en/news/296518280.md) - [Omdia: Foldable smartphone shipments will double to 36 million units by 2028. | TTGT Stock News](https://longbridge.com/en/news/296455533.md) - [Innovent Biologics files HKEX next-day return, share capital rises by 1,882,334 shares](https://longbridge.com/en/news/291949969.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**